To find a reference on this page either scroll or hold down the "Ctrl" key and press "f".
|
I f current inhibitors
|
| ivabradine - Corolan - angina (New drug) 30(2) 50-55 |
|
Ialex
|
| see cephalexin 27(5) 131-3 |
|
ibopamine
|
| dopamine cardiovascular pharmacology 17(2) 44-5 |
|
ibuprofen
|
| and asthma 27(4) 87 |
| in childhood fever (letter) 27(3) 55-7 |
| codeine combination - Nurofen Plus (New combination) 25(4) 94-9 |
| Nurofen (New formulation) 23(6) 137-9 |
|
ifosfamide
|
| cancer chemotherapy - Holoxan (New drug) 17(1) 6-8 |
|
IgE
|
| allergy testing 25(4) 91-3 |
| omalizumab - anti-IgE monoclonal antibody - Xolair (New drug) 26(6) 146-51 |
|
Ikorel
|
| see nicorandil 22(1) 20-3 |
|
iloprost
|
| Ventavis - pulmonary hypertension (New drug) 27(3) 76-9 |
|
imatinib
|
| adult leukaemia 29(3) 76-9 |
| chronic myeloid leukaemia - Glivec (New drug) 24(5) 129-31 |
|
imiglucerase
|
| Gaucher's disease - Cerezyme (New drug) 22(4) 95-8 |
|
Imigran
|
| see sumatriptan 19(2) 38-40 |
|
imiquimod
|
| genital and perianal warts - Aldara (New drug) 22(1) 20-3 |
|
immunisation - see vaccination
|
|
immunocytochemistry
|
| abnormal laboratory results 30(5) 128-9 |
|
immunoglobulin E
|
| omalizumab - anti-IgE monoclonal antibody - Xolair (New drug) 26(6) 146-51 |
|
immunoglobulins
|
| allergy testing 25(4) 91-3 |
| Rhesus D (New strength) 24(4) 100-2 |
| Rhesus D - blood donation (letter) 24(4) 80-2 |
|
immunophenotyping
|
| abnormal laboratory results 30(5) 128-9 |
|
immunosuppressants
|
| basiliximab - kidney transplantation - Simulect (New drug) 22(4) 95-8 |
| clinical and experimental pharmacology 29(4) 99-101; 29(4) 102-8 |
| everolimus - Certican (New drug) 28(3) 75-9 |
| in myasthenia gravis 30(6) 156-60 |
| mycophenolate mofetil - kidney transplantation - CellCept (New drug) 20(2) 45-51 |
| pimecrolimus - atopic dermatitis - Elidel (New drug) 26(6) 146-51 |
| sirolimus - renal transplantation - Rapamune (New drug) 25(4) 94-9 |
| tacrolimus - liver transplantation - Prograf (New drug) 21(3) 80-3 |
| letter 22(2) 28-31 |
| tacrolimus - therapeutic drug monitoring (letter) 20(3) 57-60 |
|
immunosuppressed patients
|
| aspergillosis - caspofungin acetate - Cancidas (New drug) 25(6) 147-51 |
|
immunotherapy
|
| in allergic disorders 26(4) 91-3 |
| in cancer (editorial) 23(1) 5 |
| letter 23(3) 55-6 |
|
Imodium
|
| see loperamide 21(3) 80-3 |
|
Imodium Advanced
|
| see Loperamide hydrochloride/simethicone 23(1) 21-3 |
|
Imovane
|
| see zopiclone 17(4) 87-90 |
|
Implanon
|
| see etonogestrel 24(2) 43-7 |
|
impotence
|
| alprostadil - prostaglandin - Caverject (New drug) 18(3) 58-9 |
| alprostadil - prostaglandin - MUSE (New formulation) 22(2) 43-7 |
| management of erectile dysfunction 21(2) 46-8 |
| sildenafil - Viagra (New drug) 21(4) 108-11 |
| tadalafil - Cialis (New drug) 26(2) 46-7 |
| vardenafil - Levitra (New drug) 26(3) 68-71 |
|
Imuran
|
| see azathioprine 26(2) 27-9 |
|
incretins
|
| exenatide - type 2 diabetes - Byetta (New drug) 30(6) 163-7 |
|
Indahexal
|
| see indapamide 22(6) 147-51 |
|
indapamide
|
| Indahexal (New brand) 22(6) 147-51 |
| Natrilix (New formulation) 22(5) 125-7 |
|
indinavir
|
| HIV - Crixivan (New drug) 19(4) 108-11 |
|
Infanrix
|
| see triple antigen 20(2) 45-51 |
| see vaccination, immunisation: specific vaccines - diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b 27(6) 159-65 |
|
infants
|
| abnormal laboratory results - paediatric biochemical tests 28(5) 126-9 |
| newborn hearing screening 26(4) 82-4 |
| nitric oxide - neonatal respiratory failure - INOmax (New drug) 31(1) 24-7 |
| overdoses of over-the-counter drugs in infantile colic 29(3) 83 |
| poractant alfa - respiratory distress syndrome - Curosurf (New drug) 28(3) 75-9 |
|
infection
|
| antibiotics for surgical prophylaxis 28(2) 38-40 |
| dental notes 28(2) 41 |
| C-reactive protein - abnormal laboratory results 30(3) 74-6 |
| infection control - intravenous catheters 26(2) 41-3 |
| letter 26(4) 75-7 |
| management of dental and oral pain 30(3) 77-9 |
|
infertility
|
| fertility testing - abnormal laboratory results 25(2) 38-40 |
| follitropin alpha - recombinant FSH - Gonal-F (New drug) 21(2) 49-55 |
| follitropin beta - recombinant FSH - Puregon (New drug) 19(4) 108-11 |
| polycystic ovary syndrome 27(5) 129-31 |
| letter 28(3) 55-8 |
|
inflammation
|
| C-reactive protein - abnormal laboratory results 30(3) 74-6 |
| management of dental and oral pain 30(3) 77-9 |
| monoclonal antibodies 29(5) 130-3 |
|
infliximab
|
| Crohn's disease - Remicade (New drug) 24(2) 43-7 |
| Remicade - Crohn's disease (New drug) 24(2) 43-7 |
| rheumatoid arthritis 27(2) 43-6 |
| tumour necrosis factor blockers in rheumatology 29(3) 67-70 |
|
influenza
|
| antiviral drugs and influenza prophylaxis (editorial) 30(2) 30-1 |
| immunisation 25(1) 5-7 |
| letter 25(3) 51-3 |
| oseltamivir - Tamiflu 24(2) 43-7 |
| pandemic preparedness and anti-viral drugs (letter) 25(3) 51-3 |
| vaccination |
| for healthy adults 30(2) 35-7 |
| letter 30(5) 116 |
| PBAC question 30(3) 83 |
| in pregnancy - information services (letters) 25(4) 79-80; 25(1) 4 |
| vaccine - Fluad (New brand) 27(2) 50-1 |
| zanamivir - Relenza (New drug) 22(3) 70-1 |
|
information services
|
| Adverse Medicine Events Line 27(2) 38 |
| evidence-based medicine 24(5) 116-9 |
| letters 25(4) 79-80; 25(1) 4 |
| internet and general practice 27(1) 16-8 |
| patient support organisations 27(1) 19-21 |
|
informed consent
|
| clinical investigations and professional indemnity (editorial) 19(4) 86-7 |
| dental implications 19(4) 97 |
| drug information 18(1) 10-1 |
| legal issues 25(5) 114-5 |
|
infusion pumps
|
| infusion pumps 18(2) 49-51 |
| letter 18(4) 84-6 |
|
inhalation devices
|
| in asthma 26(1) 5-7 |
| letter - tropical climates 26(4) 75-7 |
| combination inhalers 28(2) 26-8 |
|
Inhibace
|
| see cilazapril 20(2) 45-51 |
|
injections
|
| managing painful paediatric procedures 29(4) 94-6 |
| letters 29(6) 149-50 |
| needle changing (letter) 21(3) 60-3 |
| rational use 22(6) 145-7 |
|
INOmax
|
| see nitric oxide 31(1) 24-7 |
|
insomnia
|
| antidepressants and non pharmacological management in the elderly 18(1) 21-2 |
| management 26(4) 78-81 |
| letter 26(6) 124-5 |
| melatonin 20(4) 98 |
| zolpidem 24(1) 20-3 |
| zopiclone - Imovane (New drug) 17(4) 87-90 |
|
Inspra
|
| see eplerenone 28(5) 130-1 |
| letter 29(2) 32-5 |
|
institutional care
|
| scabies management 23(2) 33-5 |
|
insulin
|
| analogues and delivery systems 25(2) 29-31 |
| letter 25(5) 104-7 |
| delivery devices 25(6) 136-8 |
| therapy and hypoglycaemic drugs in diabetes 27(4) 93-6 |
| in untreatable type 2 diabetes 20(3) 65-7 |
|
insulin aspart
|
| NovoRapid (New brand) 23(5) 110-1 |
| NovoRapid (New drug) 24(1) 20-3 |
|
insulin detemir
|
| Levemir FlexPen - diabetes (New drug) 28(5) 130-1 |
|
insulin glargine
|
| diabetes - Lantus (New drug) 27(2) 50-1 |
| letter 27(6) 138-41 |
|
insulin glulisine
|
| diabetes - Apidra SoloStar (New drug) 30(5) 133-5 |
|
insulin resistance
|
| in polycystic ovary syndrome 27(5) 129-31 |
| letter 28(3) 55-8 |
| in schizophrenia 27(5) 118-9 |
|
Intal CFC-free
|
| see sodium cromoglycate 27(5) 131-3 |
|
integrelin
|
| in antiplatelet therapy 19(4) 98-101 |
| see eptifibatide 26(6) 146-51 |
|
intellectual disabilities
|
| Therapeutic Guidelines 22(4) 88-90 |
|
interactions - see drug interactions
|
|
interferon
|
| alfa-2a - peginterferon alfa-2a/ribavirin combination - Pegasys (New drug) 26(6) 146-51 |
| alfa-2b - peginterferon alfa 2b - chronic hepatitis C - Peg-Intron (New drug) 25(5) 120-3 |
| alfa-2b - ribavirin - Rebetron Combination Therapy (New combination) 23(1) 21-3 |
| beta-1a - in multiple sclerosis 25(2) 32-5 |
| beta-1a - Rebif (New strength) 23(3) 64-7 |
| beta-1b - in multiple sclerosis 25(2) 32-5 |
| beta-1b - multiple sclerosis - Betaferon (New drug) 19(1) 24-7 |
| peginterferon/ribavirin combination in hepatitis C 29(2) 36-9 |
|
interleukin-1 receptor antagonists
|
| anakinra - rheumatoid arthritis - Kineret (New drug) 27(6) 159-65 |
|
internet
|
| adverse drug effects reporting system and database 26(1) 7 |
| Australian Prescriber 21(3) 59 |
| letter 22(2) 28-31 |
| Australian Prescriber website user surveys 30(1) 16; 26(1) 17 |
| consumer drug information 23(4) 75 |
| DIPEx patient experiences website review 25(4) 93-4 |
| information services - evidence-based medicine 24(5) 116-9 |
| letters 25(4) 79-80; 25(1) 4 |
| online information services and general practice 27(1) 16-8 |
|
interstitial nephritis
|
| with omeprazole (medicinal mishap) 30(3) 67 |
|
intravenous catheters
|
| infection control 26(2) 41-3 |
| letter 26(4) 75-7 |
|
intravenous therapy
|
| hospital in the home 20(4) 88-9 |
|
intuition
|
| and clinical decision-making 25(1) 14-5 |
|
Invanz
|
| see ertapenem 25(4) 94-9 |
|
Invirase
|
| see saquinavir 19(4) 108-11 |
|
iobenguane
|
| MIBGen - adrenal tumour localisation (New drug) 27(5) 131-3 |
|
iodine
|
| in herbal cough mixture (letter) 24(3) 51-5 |
| in thyroid dysfunction 17(3) 70-2 |
|
Iopidine
|
| see apraclonidine 18(3) 58-9 |
|
ipratropium bromide
|
| Apoven 250 (new brand) 24(4) 100-2 |
| Apoven, Chem Mart, GenRx, Healthsense, Terry White Chemists ipratropium (New strengths) 25(5) 120-3 |
| Atrovent (New strengths) 19(3) 81-3 |
| in chronic obstructive pulmonary disease 26(2) 33-5 |
| Combivent - salbutamol combination (New combination) 22(6) 147-51 |
| DBL ipratropium (New strength) 25(6) 147-51 |
| GenRx ipratropium (New brand) 24(1) 20-3 |
| Ipratrin uni-dose (New brand) 20(3) 77-9 |
| Ipratrin uni-dose (New strength) 21(3) 80-3 |
|
irbesartan
|
| with hydrochlorothiazide - Avapro HCT, Karvezide (New combinations) 23(6) 137-9 |
| hypertension - Karvea, Avapro (New drug) 21(2) 49-55 |
|
Iressa
|
| see gefitinib 26(4) 94-5 |
|
irinotecan
|
| colorectal cancer 25(5) 108-10; 25(5) 111-3 |
| colorectal cancer - Camptosar (New drug) 21(2) 49-55 |
| New brand 28(3) 75-9 |
|
iron chelating agents
|
| deferiprone - thalassaemia - Ferriprox (New drug) 26(3) 68-71 |
|
iron deficiency
|
| laboratory results 20(3) 74-6 |
| thalassaemia screening 24(5) 120-3 |
| letter 25(2) 27-8 |
|
iron overload
|
| deferasirox - Exjade (New drug) 29(4) 112-5 |
|
iron sucrose
|
| Venofer - iron deficiency anaemia in haemodialysis 28(2) 49-51 |
| letter 28(4) 84-7 |
|
irritable bowel syndrome
|
| management - coeliac disease diagnosis (letter) 25(2) 27-8 |
| tegaserod - Zelmac (New drug) 25(3) 74-5 |
| advertising (editorial comment) 26(3) 67 |
|
Ismelin
|
| see guanethidine 17(3) 73 |
|
isomaltulose
|
| sugar substitute - warning in fructose metabolism disorders (letter) 31(1) 3-4 |
|
isomerism
|
| chiral drugs - pharmacology and efficacy 27(2) 47-9 |
| correction 28(3) 55-8 |
| letter 27(5) 109-13 |
|
isoniazid
|
| in human milk (letter) 21(1) 5-8 |
|
isoprenaline
|
| management of cardiac arrest 20(2) 41-5 |
|
isosorbide dinitrate
|
| new brand - Sorbidin 17(2) 30-2 |
|
isosorbide mononitrate
|
| Arsorb (New brand) 27(1) 21-3 |
|
isotretinoin
|
| in acne 28(3) 59-61 |
| new formulation - Isotrex 17(2) 30-2 |
| Oratane (New strength) 24(4) 100-2 |
|
Isotrex
|
| see isotretinoin 17(2) 30-2 |
|
itraconazole
|
| antifungal drug - Sporanox (New drug) 17(4) 87-90 |
| in cutaneous fungal infections 19(3) 72-5 |
| Sporanox (New formulation) 21(3) 80-3 |
|
ivabradine
|
| Corolan - angina (New drug) 30(2) 50-55 |
|
ivermectin
|
| pediculosis capitis 23(3) 62-3 |
| letters 24(1) 3; 23(5) 93-6 |
| scabies management 23(2) 33-5 |
| strongylodiasis and onchocerciasis - Stromectol (New drug) 20(3) 77-9 |
| Stromectol (New strength) 22(6) 147-51 |
Home
